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Abstract
Mutations in VPS35 (PARK17) cause autosomal dominant, late onset Parkinson’s disease (PD). VPS35 forms a core component of
the retromer complex that mediates the retrieval of membrane proteins from endosomes back to either the Golgi or plasma
membrane.While aberrant endosomal protein sorting has been linked to several neurodegenerative diseases, themechanisms
by which VPS35 mutations and retromer function contribute to PD pathogenesis are not clear. To address this, we generated
transgenic Drosophila that express variant forms of human VPS35 found in PD cases and the corresponding variants of the
Drosophila ortholog. We did not find evidence of dominant toxicity from any variant form including the pathogenic D620N
mutation, even with aging. However, assessing the ability of Vps35 variants to rescue multiple vps35-mutant phenotypes, we
found that the D620N mutation confers a partial loss of function. Recently, VPS35 has been linked to the formation of
mitochondria-derived vesicles, which mediate the degradation of mitochondrial proteins and contribute to mitochondrial
quality control. This process is also promoted by two other PD-lined genes parkin (PARK2) and PINK1 (PARK6). We demonstrate
here that vps35 genetically interacts with parkin but interestingly not with pink1. Strikingly, Vps35 overexpression is able to
rescue several parkin-mutant phenotypes. Together these findings provide in vivo evidence that the D620N mutation likely
confers pathogenicity through a partial loss of function mechanism and that this may be linked to other known pathogenic
mechanisms such as mitochondrial dysfunction.
Introduction
Parkinson’s disease (PD) is a common neurodegenerative dis-
order that is principally characterized by the progressive loss of
motor control and degeneration of dopaminergic neurons in
the basal ganglia. Although current treatments provide tempor-
ary symptomatic relief, their efficacy declines and the condition
is currently incurable. A greater understanding of the pathogenic
mechanisms would allow the development of more rational dis-
ease-modifying interventions. In recent years, genetic analysis of
Mendelian forms of PD has shed tremendous light on the mo-
lecular players in pathogenesis. Recently, a missense mutation,
Asp620Asn (D620N), in VPS35 (PARK17) was identified in a num-
ber of families with dominantly inherited, late-onset PD (1,2).
Additional variants, including P316S, R524W and L774M, have
also been found in sporadic patients, but their presence also in
unaffected controls has rendered the pathogenicity of these un-
certain (1,2).
VPS35 is a central component of the highly conserved retro-
mer complex that mediates the retrieval of transmembrane
cargo proteins from endosomes (3,4). Cargo-selective sorting is
critical for regulating the proper sub-cellular destination of endo-
somal proteins. The most widely characterized role for retromer
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is in the recycling of transport proteins, such as the cation-
independentmannose 6-phosphate receptor (5) orWnt transport
protein Wntless (6–8), back to the trans-Golgi network (TGN).
More recently, the cargo-selective retromer complex has also
been shown to recruit the actin nucleation promoting Wiskott–
Aldrich syndrome and SCAR homolog (WASH) complex to endo-
somes (9–11), mediated directly via VPS35 (12). This promotes
the recycling of specific cargo, such as the β2-adrenergic receptor
and the glucose transporter GLUT1, directly back to the plasma
membrane (13).
Current literature on the impact of the pathogenic D620Nmu-
tation on retromer function presents conflicting results on
whether endosome-to-TGN and/or endosome-to-plasma mem-
brane recycling is affected (14–16), or in fact whether VPS35 var-
iants confer dominant toxicity or are functionally hypomorphic
(14,17,18). However, recent studies have revealed that the
pathogenic D620N mutation inhibits VPS35 binding to the
WASH complex, consistent with a partial loss of function
(15,16). Nevertheless, much still remains to be clarified on the
pathogenic nature of VPS35 mutations and the mechanism(s)
by which they cause neurotoxicity, especially in vivo.
A surprising development in the emerging complexity of ret-
romer function was the report that Vps35 appears tomediate the
formation and trafficking of mitochondria-derived vesicles
(MDVs) (19). Similar to endosomes, theseMDVs are also cargo se-
lective and have a variety of destinations, including peroxisomes
and lysosomes (19,20). The precise role of theseMDVs is currently
uncertain but is likely to provide a route for mitochondrial com-
ponent degradation and thus a mechanism of mitochondrial
quality control (20,21). Moreover, recent evidence indicates that
two genes causative for autosomal-recessive parkinsonism,
PINK1 (PARK6) and parkin (PARK2), promote the formation of
cargo-specific MDVs targeted for lysosomal degradation (22), im-
plicating this process in the pathogenesis of PD.
Here, we sought to develop a simple in vivo model of VPS35-
related PD using Drosophila in order to address the relative patho-
genicity of known variants and to shed light on the possible
pathogenic mechanisms. Expressing variant forms of human
VPS35 or the equivalent mutations in Drosophila vps35, we
found no evidence of dominant toxicity, even with ageing.
In contrast, all variants functioned similar to wild-type (WT),
being able to substantially rescue vps35-mutant phenotypes in-
cluding one assay of endosome-to-TGN recycling. However,
some assays showed that mutant Vps35 functioned less well
thanWT, suggesting that theymay be hypomorphic. Interesting-
ly, we observed a strong genetic interaction between vps35 and
parkin, where double heterozygotes presented a synergistic loss
of dopaminergic neurons, an enhanced climbing defect that
was exacerbated with age and a striking sensitivity to paraquat.
In genetic rescue experiments, vps35 overexpression substantial-
ly suppressed several parkin-mutant phenotypes but not vice
versa. Thus, our genetic studies suggest that vps35 variants asso-
ciated with PD are likely to confer pathogenicity by haploinsuffi-
ciency rather than a toxic gain of function and suggest that
mitochondrial quality control may be an important pathway in
vps35-meditated pathogenesis.
Results
No dominant toxicity from vps35 pathogenic variants
Vps35 is highly conserved with human and Drosophila protein
homologs sharing 61% identity and 78% similarity (Fig. 1A). To
investigate the pathogenicity of vps35 mutations in vivo, we
generated transgenic Drosophila that express variant forms of
human VPS35 or, where these residues are conserved, equivalent
variants of Drosophila vps35. Since residues R524, D620 and L774
are conserved in Drosophila Vps35, while P316 is not, we focussed
our analysis on thesemutations. TransgenicDrosophilawere gen-
erated that express WT and variant forms of either human or
Drosophila vps35 under the control of the GAL4/UAS system.
Here, we designate the variants of human VPS35 as hWT,
hD620N, h524WandhL774M,while theDrosophila equivalent var-
iants are designated dWT, D650N, dR550W and dL800M.
Expression of the human Vps35 variants was verified by im-
munoblotting (Fig. 1B). Reliable antibodies against Drosophila
Vps35 are not currently available, but we assume approximately
equivalent expression levels due to the site-specific integration
of the transgenes.
Since VPS35 mutants cause autosomal dominant PD, we first
assessed whether expression of these transgenes caused domin-
ant phenotypes associated with neuronal toxicity. We analysed
effects on lifespan, retinal degeneration and locomotor activity;
however, no apparent toxicity was observed from expression of
all the transgenes (Fig. 1C–E). Moreover, no defects in motor abil-
ity appeared even after ageing (Fig. 1F and G). To enhance expres-
sion to physiologically relevant levels (see below), we also raised
and aged animals at 29°C. Under these conditions, transgenic an-
imals showed a rather modest, albeit significant, impairment to
lifespan compared with controls, but all Vps35 variants showed
equivalent effects (Supplementary Material). However, there
was still no significant effect on climbing behaviour compared
with controls at either 1–4 days or 10 days old, across all transgenic
lines.
Vps35 variants confer partial loss of function
Since no phenotypes were observed from overexpression in aWT
background, it was essential to determine whether the trans-
genes faithfully replicated Vps35 functionality. A definitive test
is to determine whether transgene expression can substitute
for endogenous vps35 function by rescuing mutant phenotypes.
Loss of function mutations in Drosophila vps35 cause severe de-
velopmental defects resulting in larval-stage lethality and the
appearance of melanotic masses in various homozygous and
transheterozygous combinations (6–8). All transgenes were ex-
pressed in a vps35 transheterozygous-mutant background
(vps35MH20/vps35E42), and viability was determined. Surprisingly,
despite using a strong ubiquitous driver, animals raised under
standard conditions (25°C) showed no rescue of viability with
any of the Vps35 variants (data not shown), so we raised animals
at a higher temperature (29°C) to increase transgene expression
levels (Fig. 1B). Expression of all variants of Drosophila vps35 was
now sufficient to prevent the appearance of melanotic masses
and fully rescue the developmental lethality, with progeny emer-
ging in expected proportions. However, while the human VPS35
variants rescuedmutant viability to late pupal stage, adults failed
to eclose indicating that human VPS35 protein cannot fully sub-
stitute for the Drosophila orthologue. In light of these results, all
subsequent rescue experiments were performed with animals
grown at 29°C.
vps35mutants showdefective development of the neuromus-
cular junction (NMJ), caused in part by aberrant bone morpho-
genic protein signalling. Loss of vps35 leads to the formation of
supernumerary boutons (Fig. 2A and B). This developmental
defect in the NMJ is accompanied by a dramatic reduction in
the larval locomotion (Fig. 2C). Expression of all variants of Dros-
ophila and human Vps35 was able to completely restore normal
Human Molecular Genetics, 2015, Vol. 24, No. 21 | 6107
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article/24/21/6106/608932 by guest on 07 O
ctober 2020
Figure 1. No dominant toxicity of human or Drosophila Vps35 variants. (A) ClustalW2 Alignment of Vps35 amino acid sequence from human (hVps35) and Drosophila
(dVps35) with the missense mutations highlighted. (B) Immunoblot of human Vps35 transgenes raised at different temperatures to monitor relative expression levels.
(C) Transgene expression does not affect lifespan when expressed ubiquitously with da-GAL4 [all not significant (ns) compared with control, Log-rank test, n = 40–100
animals]. (D) No overt phenotype is seen when the transgenes were expressed in the compound eye by GMR-GAL4. (E–G) Ubiquitous expression does not affect
climbing ability with age [all not significant (ns) compared with control]. n = 25–40 (E), 20–40 (F) and 10–40 (G). Histograms show mean ± SEM. Statistical analysis was
one-way analysis of variance (ANOVA) with Bonferroni’s correction. Control genotypes are heterozygous GAL4 driver line alone.
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NMJ formation (Fig. 2A andB). However, the larval locomotion de-
fect showed amore variable response (Fig. 2C). While the expres-
sion of WT dVps35 could completely restore locomotion to
control levels, expression of WT hVps35 could also substantially
rescue this deficit. In contrast, the missense variants of both
dVps35 and hVps35 could only partially substitute for loss of
vps35 for this phenotype.
The ability of the Drosophila transgenes to successfully rescue
vps35-mutant viability allowed us to further test the relative
functionality of the mutant variants using the climbing assay.
Figure 2.Variable effects of Vps35 variants to rescue synaptic overgrowth and locomotor phenotypes. (A) Anti-HRP immunofluorescence reveals ‘overgrown’NMJs in vps35
mutants. Scale bar = 10 µm. (B) Quantification shows significantly more synaptic boutons in vps35 mutants. n = 17–34 animals. All transgenes (Tg) provide a significant
complete rescue of this phenotype. (C) vps35 mutants display defective larval locomotion, measured by the number of peristaltic waves per 2 min. n = 5–14 animals.
All transgenes provide some rescue of this phenotype, but the variant forms are substantially less effective here. (D) Climbing assay of vps35 mutants expressing
Drosophila vps35 transgenes. n = 30–46 animals. All animals were raised at 29°C. Statistical analysis: ns = not significant, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001;
one-way ANOVAwith Bonferroni’s correction. Control genotype is heterozygous da-GAL4 driver line alone.
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This higher-order behavioural test revealed that expression of
the dWT or dL800M variant enabled comparable climbing cap-
acity with controls (Fig. 2D). In contrast, the dD650N pathogenic
mutation, and to a lesser extent the dR550W variant, produced
a clear climbing defect (Fig. 2D).
The retromer function of Vps35 has been shown to regulate
the secretion of wingless (Wg) in the larval wing imaginal disc.
Failure of the retromer complex to recycle the Wg transporter
protein Wntless leads to an intracellular accumulation of Wg
and concomitant signalling defects. This can be observed by
increased immunostaining of Wg in vps35-mutant clones com-
pared with neighbouring WT tissue (Fig. 3A and B), as previously
reported. To further test the relative function of Vps35 variants,
we sought to determine how well they could restore Wg levels
in vps35-mutant wing discs. To allow comparison within the
same tissue, we analysed wing discs from vps35-mutant animals
in which Vps35 transgene expression was restricted to the pos-
terior compartment via induction with hedgehog-GAL4 (Fig. 3C).
While the expression of all transgenes reduced the aberrant Wg
levels, quantification across multiple samples showed that all
variants restored the levels of Wg to a similar degree (Fig. 3D).
Taken together, the preceding results indicate that not only
do the Vps35 variants appear to not confer any major dominant
toxicity, but all variants appear to function largely normally in
endosome-to-plasma membrane recycling. However, while NMJ
structural defects are restored by all Vps35 variants, in functional
locomotor assays, the pathogenic variants consistently reveal a
partial loss of function.
Vps35 genetically interacts with parkin but not pink1
Since our analysis of transgenic Vps35 variants provided no evi-
dence for a toxic pathologic mechanism in our model system, we
next sought to determine whether vps35 mutations may influ-
ence other pathogenic causes. One putative link came from the
observations that Vps35 appears to play a role in the generation
of MDVs. Importantly, this process was also recently linked to
PINK1 and parkin, two autosomal-recessive PD genes strongly im-
plicated in mitochondrial quality control. MDVs have been pro-
posed to function as part of the quality control mechanism as
some vesicles carrying oxidised protein cargoes are trafficked to
the lysosome for degradation. Thus, we tested whether vps35
may genetically interact with parkin and pink1.
Animals heterozygous for vps35 or parkin show no phenotype
compared with WT; however, we found a significantly worse
climbing ability in vps35/+;parkin/+ double heterozygotes, analys-
ing two independent alleles of vps35 (Fig. 4A–F). Interestingly, this
synergy was age dependent; not apparent in young animals, but
worsening in older animals. These observations suggest that par-
kin and vps35may partly act in a common pathway, and one that
is an age-related process.
Oxidative stress is a prominent feature of PD pathology and of
normal ageing. Many models of PD show sensitivity to oxidative
stressors such as paraquat, including Drosophila parkin mutants
(Fig. 4G). Similar to the locomotor assay,while the single heterozy-
goteswere relatively insensitive, we found a synergistic sensitivity
of vps35/+;parkin/+ double heterozygotes to paraquat exposure,
comparable in severitywith parkinhomozygotes (Fig. 4G). Interest-
ingly, we also saw a genetic interaction of vps35 and parkin in the
degeneration of DA neurons of the PPL1 cluster after 30 days
(Fig. 4H).
Sincecombining loss of functionmutations caused theappear-
ance of pathogenic phenotypes, we reasoned that overexpression
of either vps35 or parkin may ameliorate mutant phenotypes of
the other gene. vps35mutants are developmental, lethal and pre-
sent characteristicmelanoticmasses in larvae (7). Strong, ubiqui-
tous overexpression of parkin in vps35 mutants was unable to
rescue these phenotypes (data not shown). However, we found
that overexpression of vps35 significantly rescued many of the
parkin phenotypes, including the climbing defect and sensitivity
to paraquat (Fig. 5A, C andD), with all variants of eitherDrosophila
of humanVps35 providing an equivalent degreeof rescue. In con-
trast, the flight defect in parkin mutants was not suppressed by
vps35 overexpression (Fig. 5B).
Substantial evidence supports a role for PINK1 and Parkin to
act, at least partly, in a common pathway, so we also tested for
genetic interaction between vps35 and pink1. In contrast to the
previous results, we found no synergy in vps35/+;pink1/+ double
heterozygotes, even after ageing (Fig. 6A–F). We also found
vps35 overexpression did not rescue pink1 phenotypes (Fig. 6G,
H and data not shown), nor did pink1 overexpression alter vps35
phenotypes (data not shown). In fact, while vps35 overexpression
did not alter the pink1 climbing defect, it actually worsened the
flight defect (Fig. 6H). Thus, while the preceding results indicate
a strong genetic interaction between vps35 and parkin, surprising-
ly, there appears to be no genetic interaction between vps35 and
pink1.
Discussion
Mutations in VPS35 cause a late-onset, autosomal dominant
form of PD. Replicating genetic mutations in classic model
systems has been a powerful approach in illuminating the patho-
genic mechanisms. One key issue in the molecular understand-
ing of pathogenicity, especially with mutations causing dominant
forms of disease, is to determine the basic mode of toxicity that
can be broadly predicted to be toxic gain of function, dominant
negative and/or haploinsufficiency through partial loss of
function.
Current literature analysing the impact of the D620N muta-
tion on the cell biological function of the retromer complex pre-
sents conflicting results as to whether endosome-to-TGN and/or
endosome-to-plasma membrane recycling is affected (14–16).
However, despite discrepancies on which trafficking routes may
be perturbed, there is a general consensus that D620N has im-
paired function compared with WTwithout overt dominant tox-
icity (14–16,23). Evidence for the molecular basis of this
dysfunction indicates that D620N specifically disrupts the re-
cruitment of the WASH complex to endosomes by decreased
binding of VPS35 to the WASH component FAM21 (15,16). These
findings argue for partial loss of function from this pathogenic
mutation, rather than toxic gain of function. Our results largely
support these findings. First, our data provide clear evidence
that transgenic expression of WT or variant forms of vps35 does
not cause overt toxicity. Second, all variants of Vps35 appear to
function near normally as they are able to substantially rescue
vps35-mutant phenotypes, including viability, NMJ morphology
andWg secretion. Interestingly, while the WT form of both Dros-
ophila and human Vps35 could substantially rescue a larval loco-
motor defect, the variant forms could only provide partial rescue
consistent with a partially reduced functionality. Furthermore,
although the pathogenic dD650N variant could rescue vps35mu-
tants to adult viability, these animals revealed a distinct loco-
motor deficit in contrast to the WT and non-pathogenic
dL800M. The locomotor activity assays provide a highly sensitive
read-out of the complex neuromuscular circuit. Even small dis-
turbances in function at any part of this circuit will result in a
quantifiable deficit. Thus, the failure of the Vps35 pathogenic
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Figure 3. All transgenes rescue Wg secretion in vps35 mutants. (A) Anti-Wg immunostaining (green) reveals intracellular accumulation of Wg in FLP/FRT clones of
vps35MH20 in wing imaginal discs. Loss of anti-β-gal immunostaining (red) marks the clones lacking vps35. (B) Quantification of relative anti-Wg immunostaining in
vps35 clones compared with neighbouring WT tissue. Histogram shows mean ± SEM. n = 15 ROIs from nine animals. (C) Wing imaginal discs from vps35 null mutants
in which hh-GAL4 drives expression of Vps35 transgenes in the posterior half along with an red fluorescent protein marker (red). (D) Quantification of the relative
immunofluorescence from anterior (mutant) versus posterior (rescued) segments of Wg expression domain. Histogram shows mean ± SEM. n = 5–6 discs per genotype,
analysed by one-way ANOVAwith Bonferroni’s correction (ns = not significant). Scale bar = 10 µm.
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Figure 4. vps35 genetically interacts with parkin. (A–F) Climbing ability was assessed at different ages in animals single and double heterozygous for null alleles of parkin
(park25) and two independent null alleles of vps35, vps35MH20 (A–C) and vps35E42 (D–F). n = 38–48 (A), 42–75 (B), 36–54 (C), 50–63 (D), 63–80 (E) and 44–64 (F). (G) Survival
analysis of single and double heterozygotes, alongside park25 homozygotes, exposed to 5 m paraquat (PQ). n = 8–60 animals. (H) Analysis of dopaminergic neuron
loss in the PPL1 cluster in 30-day-old animals. n = 17, 22 and 16, respectively. Histograms show mean ± SEM. Statistical analysis: ns = not significant, **P < 0.01,
***P < 0.001 and ****P < 0.0001; one-way ANOVAwith Bonferroni’s correction, or Log-rank test for survival.
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variants to fully rescue this phenotype likely reflects a subtle de-
crease in functionality.
A recent study of lentiviral-mediated overexpression of VPS35
in cortical neurons reported neurotoxic effects in vitro and in vivo;
however, the effects of D620Nwere often similar to that of overex-
pressing WT VPS35 (17). Thus, although it was proposed that
where the effect of D620N overexpression differed from overex-
pression of WT, this was due to some gain-of-function toxicity,
the effects could also result from the reduced function of D620N
acting as a partial dominant negative when overexpressed.
The disruption of VPS35 D620N binding to FAM21 suggests a
plausible pathogenic mechanism since this appears to affect
the trafficking of the autophagy protein ATG9A and subsequent
induction of autophagy (16). Since autophagy is a keymechanism
for degradation of cellular components such as long-lived pro-
teins, large aggregates and defective organelles, autophagy
inhibition is considered a major culprit in the pathogenesis of
neurodegenerative diseases including PD. It is notable that
VPS35 haploinsufficiency has been reported to enhance neuro-
pathology in a mouse model of Alzheimer’s disease (24), where
Figure 5.Overexpression of vps35 rescues some parkin-mutant phenotypes. Ubiquitous overexpression of all variants of Drosophila or human vps35 rescues parkin-mutant
climbing defect (A), but not the flight defect (B). n = 50–150 animals. Sensitivity of parkinmutants to 5 m paraquat (PQ) exposure was completely rescued by transgenic
expression of all variants of Drosophila (C) or human (D) vps35. n = 40–100 animals. Control genotype is heterozygous da-GAL4 driver line alone. Histograms show
mean ± SEM. Statistical analysis: ns = not significant, **P < 0.01, ***P < 0.001 and ****P < 0.0001; one-way ANOVAwith Bonferroni’s correction, or Log-rank test for survival.
All comparisons are with park25.
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Figure 6. vps35 does not genetically interact with pink1. (A–F) Climbing ability was assessed at different ages in animals single and double heterozygous for null alleles of
pink1 (pink1B9) and two independent null alleles of vps35, vps35MH20 (A–C) and vps35E42 (D–F). n = 77–94 (A), 53–87 (B), 27–42 (C), 23–39 (D), 50–85 (E) and 42–73 (F). (G)
Overexpression of vps35 does not suppress climbing deficits in pink1 mutants (n = 60–100 animals) but slightly enhances the flight defect (H) (n = 35–60 animals).
Histograms show mean ± SEM. Statistical analysis: ns = not significant, **P < 0.01, ***P < 0.001 and ****P < 0.0001; one-way ANOVA with Bonferroni’s correction.
Comparisons are with pink1-mutant control (pink1B9; da(GAL4)/+) unless otherwise indicated.
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amyloid plaques and neurofibrillary tangles highlight decreased
autophagy as a prominent mechanism for this disease (25). In
this context, it is highly plausible that the partial loss of function
conferred byVPS35mutationsmay lead to a haploinsufficiency of
VPS35 function related to autophagy induction in PD as well.
Partial loss of function could also affect other VPS35
functions. To date, while there is very limited evidence linking
‘classic’ retromer-mediated endosomal retrieval in PD, mito-
chondrial dysfunction has long been considered a key patho-
genic mechanism (26). Our genetic studies of vps35 with parkin
and pink1 support an involvement in Vps35 regulating mito-
chondrial homeostasis but have yielded some surprising results.
First, we uncovered a clear genetic interaction between vps35
and parkin consistent with the two genes functioning in a com-
mon process. Parkin has been linked to the regulation of many
cellular processes (27), but by far the most prominent is the au-
tophagic degradation of damaged mitochondria, or mitophagy,
a mechanism of mitochondrial quality control (28). Recently, it
was shown that an early mechanism of Parkin-mediated mito-
chondrial homeostasis was in the generation of MDVs (22), pre-
viously also linked to VPS35 function (19). Clearly, more work is
needed to elucidate the precise mechanisms linking vps35 func-
tion to parkin; however, our results are consistent with Vps35
and Parkin cooperating in such a mitochondrial quality control
process and provide the first in vivo evidence for a functional
interaction.
Given this robust vps35-parkin genetic interaction, the lack of
evidence for a genetic interaction between vps35 and pink1 was
surprising given the substantial body of evidence linking the
functions of PINK1 and Parkin (28), and the fact that PINK1 also
appears to promoteMDV formation (22). Nevertheless, this result
adds further weight to the growing evidence that PINK1 and Par-
kin have independent as well as common functions. Most not-
ably, PINK1 has been suggested to regulate the activity of
Complex I of the respiratory chain independent of its role in mi-
tophagy or Parkin (29,30).
The characterization of these new Drosophila models of PD
provides in vivo evidence that dominant mutations in VPS35 like-
ly do not act via a dominant toxic gain of function but rather
through a partial loss of function conferring an age-dependent
haploinsufficiency. Moreover, our genetic studies provide further
support for vps35 deficiency impacting on mitochondrial quality
control processes. Further workwill be needed to understand the
full spectrum of VPS35 and retromer function on cellular homeo-
stasis, but these models provide a platform with which to eluci-
date this in the context of the ageing brain.
Material and Methods
Drosophila genetics
Drosophilawere raised under standard conditions at 25°C on food
consisting of agar, cornmeal and yeast unless otherwise stated.
The UAS-hVPS35 transgenes were generated by sub-cloning
human VPS35 variants, kindly provided by T. Strom, into pUAS-
TattB vector using primers introducing 5′NotI and 3′XhoI cloning
sites. The UAS-dVps35 transgenes were similarly generated by
sub-cloning the full length Drosophila Vps35 cDNA (clone
SD03023 from the Drosophila Genomics Resource Center) into
pUASTattB. Variants of dVps35 were generated by standard site-
directed mutagenesis prior to sub-cloning. All constructs were
verified by sequencing. Transgenic lines were made using the
phiC31method using target strain PBac{y[+]-attP-3B}VK00031, in-
tegrating the transgene at cytological location 62E1 (BestGene,
Inc.). At least three lines of each variant were initially tested for
consistency before focussing on a single line.
The vps35MH20 and vps35E42 alleles and UAS-vps35-HA have
been described before (7,8) and were kindly provided by J.-P. Vin-
cent (Crick Institute) andK. Basler (IMLS, Zurich). pink1B9mutants
(31) were kindly provided by J. Chung (SNU). park25mutants have
been described before (32). Stocks to analyse vps35 function in
wing discs, hh-GAL4, UAS-red fluorescent protein and Ubx-FLP;
FRT42D arm-lacZ were kindly provided by D. Strutt. w1118, da-
GAL4 andGMR-GAL4 strainswere obtained from the Bloomington
Drosophila Stock Center (Bloomington, IN).
Behavioural assays
Fertility tests, flight and climbing assays were performed as pre-
viously described (32,33), with only males assessed here. Larval
crawling was performed using animals grown at 29°C. Third in-
star larvae expressing the indicated vps35 transgene using da-
GAL4 in the vps35-mutant background were collected from
vials, briefly rinsed with distilled water and placed on 2% agar.
Movies were captured, which were then analysed manually, re-
cording the peristaltic waves per 2 min for each larva.
For lifespan analysis, animals were raised in low density, and
shortly following eclosion, 40–100 adult flies were separated by
gender and kept in groups of 15 flies per vial. The number of
deathswas recorded every 2 or 3 days as the flieswere transferred
to new media. Survival upon exposure to paraquat was per-
formed similarly, except flies were kept in vials with filter paper
soaked with 5 m paraquat in 5% sucrose. Survival was analysed
by Log-rank (Mantel–Cox) test. For all the experiments, unless
otherwise indicated, only males were used.
Immunoblotting
Proteins were prepared in lysis buffer (50 m Tris–HCl, 150 m
NaCl, 10% [vol/vol] glycerol, 1% Triton X-100, 10 m N-ethylma-
leimide, 2 m ethylene glycol tetraacetic acid, 1 m, MgCl2,
50 µ MG-132 and protease inhibitor mixture [Roche]), and
60 µg were loaded on SDS-PAGE gels. After resolving, proteins
were transferred onto PVDF membrane. Membranes were
blocked by 5% skimmed milk, 1% foetal bovine serum (FBS) in
Tris-Buffered Saline with 0.1% Tween 20. Rabbit anti-VPS35 (Pro-
teintech 10236–1-AP, 1:500) was incubated in blocking solution
overnight at 4°C. Mouse anti-Actin (Millipore MAB1501, 1:10 000)
was incubated in blocking solution at room temperature (RT) for
1 h. Membranes were washed repeatedly in phosphate-buffered
saline (PBS)–0.1% Tween 20 (PBST), and then appropriate horse-
radish peroxidase (HRP)-conjugated secondary antibodies were
incubated for 1 h at RT. Detection was achieved with ECL-Plus
detection kit (Amersham) using radiographic film.
Immunohistochemistry
Wandering third instar larvae were selected for NMJ analysis es-
sentially as previously described (34). Larval body wall muscles
were dissected in a saline containing 128 m NaCl, 2 m KCl,
4 m MgCl2, 0.1 m CaCl2, 35.5 m sucrose and 5 m Hepes
(pH 7.2), and fixed in a freshly prepared ice-cold 4% paraformal-
dehyde for 20 min.
The preparations were then washed in PBST for three times
in 15 min, followed by 1 h blocking in 5% FBS in PBST. Samples
were incubated overnight at 4°C with anti-HRP antibody (Jackson
Immunoresearch Laboratories, used at 1:200) and anti-discs large
(4F3, Developmental Studies Hybridoma Bank, used at 1:300).
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Secondary antibodies (Invitrogen) AlexaFluor 594 goat anti-rabbit
(1:500) and AlexaFluor 488 goat anti-mouse (1:500) were used,
respectively.
Quantification of bouton number was performed on longitu-
dinal muscle 6/7 at segment A2 as previously described (35).
Total number of boutons (Type 1B and 1S) was counted on
Olympus FV1000 microscope under Plan Apo 60X (N.A. 1.42) oil
immersion lens. The number of boutons was normalized to the
respective muscle surface area. Muscles were photographed at
a 10× magnification, and the area was quantified using Image J
software.
Wing discs were analysed essentially as previously described
(36). Wandering third instar larvae were dissected and fixed for
1 h at RT in 4% paraformaldehyde. They were then washed
twice for 15 min with PBS containing 0.1% Triton X-100 (PBST),
blocked for 1 h with PBS with 1% bovine serum albumin. The
samples were then incubatedwith anti-Wg (1:40; Developmental
Studies Hybridoma Bank, Iowa) and anti-β-gal (1:1000, Cappel) in
blocking buffer overnight at 4°C with rotation. The next day, the
samples werewashed twicewith PBST for 15 min each, following
which they were incubated with AlexaFluor-488 goat anti-mouse
antibody and AlexaFlour-546 anti-rabbit antibody for 1 h. The
samples were then washed twice for 15 min each with PBST, fol-
lowing which thewing discs weremounted inMowiol and stored
at 4°C until imaging. Images were captured using Nikon Eclipse
T1 confocal microscope with a 40× (N.A. 1.3) oil immersion
objective.
For quantification of Wg levels, following projections of
Z-stacks for each wing disc, regions of interest (ROIs) were
marked inside the clone and ROIs of the same dimensions were
marked on the neighbouring WT tissue. Measurement of inten-
sities of Wg staining was obtained, and the intensity per unit
area was calculated for each of the mutant and WT ROI. Data
were analysed using paired Student’s t-test.
Dopaminergic neuronswere analysed as described previously
(37). Anti-tyrosine hydroxylase (Chemicon AB152) was used at
1:200. Quantification was done with the experimenter blind to
the genotype of the samples.
Statistical analysis
Calculations and statistical analysis were performed using Excel
(Microsoft Corporation, Redmond, WA) and Prism software
(GraphPad Software, Inc., San Diego, CA). Statistical significance
was determined by one-way ANOVAwith Bonferroni’s correction
for multiple comparisons or by Student’s t-test. All data shown
were obtained fromat least three independent experiments. Life-
span and paraquat survival were analysed by Log-rank (Mantel–
Cox) test.
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Supplementary Material is available at HMG online.
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